The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of MET exon 14 skipping in Chinese non-small cell lung cancer (NSCLC) patients.
 
Baihua Zhang
No Relationships to Disclose
 
Yu Xia
No Relationships to Disclose
 
Jiujin Zhang
No Relationships to Disclose
 
Jin Yu
No Relationships to Disclose
 
Min Chen
No Relationships to Disclose
 
Wei Yao
No Relationships to Disclose
 
Juan Zhao
No Relationships to Disclose
 
Jiqiang He
No Relationships to Disclose
 
Tony S. K. Mok
Employment - The Chinese University of Hong Kong
Leadership - AstraZeneca; Hutchison MediPharma; Sanomics Limited
Stock and Other Ownership Interests - Hutchison MediPharma; Sanomics Limited
Honoraria - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Fishawack Facilitate; Hutchison MediPharma; Ignyta; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Takeda; Vertex
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Hutchison MediPharma; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Xcovery (Inst)
 
Kai Wang
Employment - OrigiMed
Leadership - OrigiMed